Weekly Digest - 10-17 Mar 2023
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - 10-17 Mar 2023
Mar 10, 2023: Keytruda (Pembrolizumab, IV)/ Metastatic malignant pleural mesothelioma / Merck: Phase 2/3 IND.227/KEYNOTE-483 study met its primary endpoint
- Merck announced that the KEYNOTE-483 study, evaluating Keytruda with chemotherapy met its primary endpoint of overall survival in patients with metastatic malignant pleural mesothelioma.
- Study details: NCT02784171; Phase 2/3; n=520; Patients With Advanced Malignant Pleural Mesothelioma; Active, not recruiting; Pembrolizumab (200mg) with Cisplatin (75 mg/m2) & Pemetrexed (500 mg/m2); PO: Progression-free survival & overall survival
hormone-sensitive prostate cancer)- Statistically significant and clinically meaningful improvement in Overall Survival compared to chemotherapy alone.
- Safety profile of Keytruda was consistent with previously reported studies.
- Results will be presented at an upcoming medical meeting and discussed with regulatory authorities.
- “.. Patients are in need of new treatments that can improve survival outcomes, and these positive results support the potential of KEYTRUDA in combination with chemotherapy as a first-line treatment for patients with the most common form of malignant mesothelioma.” said Dr. Eliav Barr, Sr. VP & CMO of Merck Research Laboratories
